Today the FDA's Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend that BPC-157 be added to the Section 503A Bulk Drug Substances List.

KPV was also recommended for inclusion.

The committee overrode FDA staff's recommendation — which opposed the compounds under review.

This is the most significant regulatory development in the peptide compounding space in years. It is also not what most of the internet will tell you it is. Here's the precise picture.

What Happened Today

The Pharmacy Compounding Advisory Committee (PCAC) convened at FDA's White Oak Campus in Silver Spring, Maryland for Day 1 of its two-day hearing.

Four compounds were on the July 23 agenda: BPC-157, KPV, TB-500, and MOTS-c.

Confirmed votes as of this writing:

BPC-157 (free base and acetate): Recommended for inclusion — 8 yes, 6 no, 1 abstention
KPV (free base and acetate): Recommended for inclusion — confirmed by multiple outlets
TB-500 and MOTS-c: Votes occurring today — results not yet confirmed at time of publication. We will update this post as results are verified.

Day 2 (July 24) covers Emideltide (DSIP), Semax, and Epitalon.

Why the Vote Matters

The FDA staff had recommended against the compounds in their pre-meeting briefing documents. Their position: insufficient human clinical data for the proposed routes and uses, inadequate substance characterization, and unassessed immunogenicity risks. For BPC-157, staff noted only a single small human study; for KPV, no human studies were identified.

The advisory committee disagreed — at least on BPC-157 and KPV.

Committee members who voted yes generally concluded that the risks were manageable and that clinical practitioners and patients had established a meaningful case for compounding access under physician prescription.

Committee members who voted no expressed concern about safety risks, effectiveness evidence gaps, and the signal that inclusion would send.

An 8-6-1 vote is narrow. It reflects a genuinely divided expert community. This was not a landslide — it was a close call on an evidence base that reasonable experts can read differently.

What This Vote Does NOT Mean

Let's be precise, because the next 48 hours will produce a lot of inaccurate takes.

This is not legalization. BPC-157 is not legal to compound today. Nothing changed legally the moment the vote was called.

This is not FDA approval. The PCAC is an advisory committee. Its recommendations are non-binding. The FDA makes the final determination — independently.

Compounding pharmacies cannot start making BPC-157 today. The 503A Bulks List has not been updated. Until it is, the same legal framework that existed yesterday exists today.

This is not the finish line. It's the most important mile marker we've seen — but the process continues.

What Actually Happens Next

The regulatory process that follows this vote is well-defined — and slower than most people want it to be.

Step 1: Committee completes votes today and tomorrow (Day 2: Emideltide, Semax, Epitalon — July 24)

Step 2: FDA reviews the committee recommendations alongside all public comments filed to the meeting's docket (more than 1,800 public comments were submitted)

Step 3: FDA publishes a proposed rule to add the substances to the 503A Bulks List — opening a new public comment period

Step 4: FDA reviews comments on the proposed rule

Step 5: FDA publishes the final rule

Step 6: Only after the final rule is published can licensed compounding pharmacies legally compound these substances under 503A

Realistic timeline: Late 2026 at the absolute earliest. Most regulatory analysts put the realistic date in 2027.

Even with a favorable committee vote, this is a months-long process. Anyone telling you BPC-157 is "back" or "legal now" is wrong.

Why the Committee Override Is Significant

FDA advisory committees do not always override staff recommendations. When they do, it carries weight.

Ahead of the meeting, regulatory analysts noted that the committee's composition made an override a plausible outcome — and that is what occurred on BPC-157 and KPV.

The committee's makeup has been the subject of public scrutiny, with some outlets raising questions about members' clinical and commercial ties to peptide medicine. Whether that composition reflects appropriate expertise or problematic conflicts is a legitimate debate. What is clear is that it produced a different outcome than an unmodified committee following staff recommendations would have.

The FDA is not obligated to follow the committee's recommendation. But a committee vote against the staff position is a meaningful input into the FDA's final determination.

What This Means for People Tracking Their Health Right Now

Nothing changes today. The vote is a recommendation, not a rule. The legal status of these compounds is unchanged.

The path toward legal access is now on the record. For the first time, there is a formal positive committee recommendation on BPC-157 and KPV. That is a step the rulemaking process requires in order to move forward.

This post is not a recommendation to start, stop, or change any protocol. Decisions about any compound belong between a person and their licensed healthcare provider.

Keep a clear record. Whether access expands or contracts, having a clear record of what you've been doing, how your body composition has changed, and what your baseline looks like is valuable. If access changes — in either direction — your own data is how you and your doctor make informed decisions.

Day 2 matters too. Emideltide, Semax, and Epitalon vote tomorrow. We'll cover those results as they're confirmed.

The Bottom Line

An 8-6-1 vote against the FDA staff recommendation on BPC-157 is a genuine, meaningful regulatory development — not a formality, not a technicality. The committee heard the evidence, heard the public testimony, and reached a different conclusion than the staff.

It is not legalization. It is not approval. It is not immediate access.

It is the most important chapter yet in a long regulatory story — and we're not at the last page.

We'll update this post as TB-500 and MOTS-c results are confirmed, and publish a full Day 2 report after the Emideltide, Semax, and Epitalon votes tomorrow.

→ Follow every development at PeptidesGPT.com/research

Sources:

ABC News: "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list" — abcnews.com (July 23, 2026)
STAT News: "In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides" — statnews.com (July 23, 2026)
TIME: "An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition" — time.com (July 23, 2026)
NPR: "Advisers to the FDA will vote to ease regulation of popular peptides" — npr.org (July 23, 2026)
FDA.gov: Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — advisory-committees calendar

This post will be updated as remaining Day 1 vote results (TB-500, MOTS-c) and Day 2 results (Emideltide, Semax, Epitalon) are confirmed.

PeptidesGPT is an educational platform. The content above is for general informational purposes only and does not constitute medical, legal, or regulatory advice. It is not a recommendation to use, obtain, start, stop, or change any compound or protocol. Always consult a licensed healthcare provider before making decisions about your health, and qualified counsel for legal or regulatory questions.